Concomitant genomic alterations in kras mutant advanced lung adenocarcinoma

KRAS mutations are the most commonly described alterations in non-small cell lung cancer (NSCLC) Caucasian population accounting for approximately 25% of cases being more frequent in patients with adenocarcinoma histology and smoking history [1]. Although prevalent, unfortunately, no specific treatment has been successfully developed for these patients [2]. With the advent of next generation sequencing (NGS) we have become aware that KRAS-mutated tumors can be associated with co-occurring alterations in multiple genes and with a higher mutational burden [3,4].

Source: Lung Cancer - December 4, 2019 Category: Cancer & Oncology Authors: Joan Gibert, Sergi Clav é, Max Hardy-Werbin, Álvaro Taus, Pedro Rocha, Raquel Longarón, Gabriel Piquer, Imane Chaib, Enric Carcereny, Teresa Morán, Marta Salido, Alba Dalmases, Beatriz Bellosillo, Edurne Arriola Source Type: research